Development and In Vitro Evaluation of Nimodipine Transdermal Formulations Using Factorial Design

References

• Langley M. S., Sorkin E. M. Nimodipine, a review. Drugs 1989; 37: 669–699
   PubMed Web of Science ®Google Scholar
• Kazda S. Pharmacology of nimodipine, a calcium antagonist with preferential cerebrovascular activity. Neuro-chirurgia 1985; 28: 70–73
   Google Scholar
• Auer L. M. Preventive nimodipine and acute aneurysm surgery. Neurochirurgia 1985; 28: 87–92
   PubMedGoogle Scholar
• Stewart D. J., Gelston A., Hakim A. Effect of prophylactic administration of nimodipine in patients with migraine. Headache 1988; 28: 260–262
   PubMed Web of Science ®Google Scholar
• Ramsch K. D., Abr G., Tettenbom D., Auer L. M. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochirurgia 1985; 28: 74–78
   PubMedGoogle Scholar
• Yoshida A., Yamamoto M., Itoh T., Irie T., Hirayama F., Uekama K. Utility of 2-hydroxypropyl-β-cyclodex-trin in an intramuscular injectable preparation of nimodipine. Chem. Pharm. Bull. 1990; 38: 176–179
   PubMed Web of Science ®Google Scholar
• Kiigman A. M., Christophers E. Preparation of isolated sheets of human stratum comeum. Arch. Dermatol. 1963; 88: 702–709
   PubMedGoogle Scholar
• Armstrong N. A., James K. C. Understanding Experimental Design and Interpretation in Pharmaceutics. Ellis Horwood Ltd., London 1990; 27–54
   Google Scholar
• Bolton S. Pharmaceutical Statistics. Marcel Dekker, Inc., New York 1990; 308–337
   Google Scholar
• Gunst R. F., Mason R. L. How to Construct Fractional Factorial Experiments. ASQC Quality Press, Milwaukee 1991; 35
   Google Scholar
• Pugh G. A. Industrial Experiments Without Statistical Pain. ASQC Quality Press, Milwaukee 1994; 4–5
   Google Scholar
• Yates F. The design and analysis of factorial experiments, Imp. Bur. Soil Sci. Tech. Commun. 1937; 35: 125–144
   Google Scholar
• Lee C. S., Chien Y. W. Transdermal controlled delivery of progesterone: Enhancement in skin permeation rate by alkanoic acids and their derivatives. Proc. Int. Symp. Controlled Release Bioact. Mater. 1987; 14: 219–220
   Google Scholar
• Aungst B. J., Royers N. J., Shefter E. Enhancement of naloxone permeation through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides. Int. J. Pharm. 1986; 33: 225–234
   Web of Science ®Google Scholar
• Chien Y. W., Chien T. Y., Huang Y. C. Transdermal fertility regulation in females: (I) Development of transdermal contraceptive system and in vitro evaluation. Proc. Int. Symp. Controlled Release Bioact. Mater. 1988; 15: 286–287
   Google Scholar
• Lee C. S., Huang Y. C., Chien Y. W. Enhanced permeation of Nitroglycerin from a skin permeation enhancer releasing transdermal drug delivery system. Proc. Int. Symp. Controlled Release Bioact. Mater. 1987; 14: 178–179
   Google Scholar
• Shah H. S., Tojo K., Chien Y. W., Huang Y. C. Development of transdermal delivery system for Verapamil: Effect of isopropyl myristate on skin permeation. Proceed. Int. Symp. Controlled Release Bioact. Mater. 1988; 15: 410–411
   Google Scholar
• Cooper E. R. Increased skin permeability for lipophilic molecules. J. Pharm. Sci. 1984; 73: 1153–1156
   PubMed Web of Science ®Google Scholar
• Mollgaard B., Hoelgaard A. Vehicle effect on topical drug delivery II. Concurrent skin transport of drugs and vehicle components. Acta Pharm. Suec. 1983; 20: 443–450
   PubMedGoogle Scholar
• Chien Y. W., Lee C. S. Transdermal drug delivery system with enhanced skin permeability. Controlled Release Technology-Pharmaceutical Applications, P. I. Lee, W. R. Good. American Chemical Society, Washington, DC 1987, ACS Symposium Series No. 348, Chapter 21
   Google Scholar
• Morimoto Y., Sugibayashi K., Kobayashi D., Shoji H., Yamazaki J., Kirnura M. A new enhancer coenhancer system to increase skin permeation of morphine hydro-chloride in vitro. Int. J. Pharm. 1993; 91: 9–14
   Web of Science ®Google Scholar
• Ueda H., Isshiki R., Ogihara M., Sugibayashi K., Morimoto Y. Combined effect of ultrasound and chemical enhancers on the skin permeation of aminopyrine. Int. J. Pharm. 1996; 143: 37–45
   Web of Science ®Google Scholar
• Almirall M., Montana J., Escribano E., Obach R., Berrozpe J. D. Effect of d-limonene, alpha-pinene, and cineol on in vitro transdermal human skin penetration of chlorpromazine and haloperidol. Arzneim.-Forsch. 1996; 46: 676–680
   PubMed Web of Science ®Google Scholar
• Ogiso T., Nishioka S., Iwaki M. Dissociation of insulin oligomers and enhancement of percutaneous absorption of insulin. Biol. Pharm. Bull. 1996; 19: 1049–1054
   PubMed Web of Science ®Google Scholar
• Singh S. K., Durrani M. J., Reddy I. K., Khan M. A. Effect of permeation enhancers on the release of Ketopro-fen through transdermal drug delivery systems. Pharmazie 1996; 51: 741–744
   PubMed Web of Science ®Google Scholar
• Bennett S. L., Barry B. W. Effectiveness of skin penetration enhancer propylene glycol, Azone, decylmethyl-sulphoxide and oleic acid with model polar (mannitol) and nonpolar (hydrocortisone) penetrants. J. Pharm. Pharmacol. 1985; 37: 84–90
   PubMed Web of Science ®Google Scholar
• Kim D. D., Chien Y. W. Transdermal delivery of Zalcitabine: in vitro skin permeation study. AIDS 1995; 9: 1331–1336
   PubMed Web of Science ®Google Scholar
• Kim D. D., Chien Y. W. Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. The effect of vehicle and enhancer on skin permeation. J. Pharm. Sci. 1996; 85: 214–219
   PubMed Web of Science ®Google Scholar
• Cleary G. W. Transdermal drug delivery. Cosmet. Toi-letr. 1991; 106: 97–109
   Google Scholar